Cipla Launches New Non-Antibiotic Medicine for Urinary Tract Infections in India
In a big step forward for healthcare, Cipla announced on September 5 that it has launched a new treatment called HUENA, which helps prevent recurring Urinary Tract Infections (UTIs) without using antibiotics. The medication’s main ingredient is Methenamine Hippurate.
UTIs are among the most common reasons for using antibiotics in India. Over the past 30 years, the number of UTI cases has doubled, making prevention more important than ever. Women are especially affected by UTIs, accounting for about 15% of all antibiotic prescriptions in the country.
Cipla says that Methenamine Hippurate offers an effective alternative to long-term antibiotic use. It works by targeting bacteria in the bladder and urinary tract, helping prevent infections without the risk of antibiotic resistance—a growing global health concern.
Studies show that this non-antibiotic treatment is just as effective as low-dose antibiotics for preventing UTIs. Plus, it costs less and doesn’t contribute to the problem of antimicrobial resistance (AMR).
Achin Gupta, Cipla’s Global COO, shared his excitement: “Launching HUENA reflects our commitment to antimicrobial stewardship and fighting AMR. We believe this innovation will improve patient health and reduce reliance on antibiotics, paving the way for a healthier future.”
Being the first company in India to introduce this treatment, Cipla has taken a major step forward in battling antimicrobial resistance. Jaideep Gogtay, Cipla’s Global Chief Medical Officer, emphasizes the importance: “We recognize the urgent need for innovative solutions to fight AMR. Our new non-antibiotic drug provides a way to prevent UTIs without contributing to antibiotic resistance.”
In other news, Cipla recently received approval from India’s Central Drugs Standard Control Organisation (CDSCO) to market inhaled insulin. This product, called Afrezza and developed by MannKind Corporation, is a fast-acting insulin that is inhaled rather than injected. It helps adults with diabetes better control their blood sugar levels, especially when taken at mealtime. Unlike traditional insulin shots, Afrezza dissolves quickly in the lungs and enters the bloodstream fast, offering a more convenient option for many patients.
Cipla operates in 74 countries worldwide, continuing to lead with innovative healthcare solutions that aim to improve lives across the globe.
